Hepatosplenic T-cell Lymphoma (HSTCL)

A rare but aggressive lymphoma linked to immunosuppressive therapy

Medications Associated with Risk

Thiopurines: Azathioprine, 6-mercaptopurine
Anti-TNF agents: Infliximab, adalimumab
Combination therapy significantly increases risk
Rare cases with cyclosporine, tacrolimus, post-transplant regimens

Who Is Affected?

Adolescents and young adults (median age ~34)
Strong male predominance
Underlying conditions: Crohn’s disease, ulcerative colitis, autoimmune diseases, post-transplant
Risk increases with ≥2 years of thiopurine use

Clinical Manifestations

Fever, fatigue, night sweats, weight loss
Splenomegaly (nearly universal), hepatomegaly
Thrombocytopenia, anemia, neutropenia
Elevated LDH, abnormal liver enzymes
No lymphadenopathy

Diagnosis

Imaging: CT or PET shows diffuse hepatosplenomegaly
Biopsy: Liver or bone marrow confirms diagnosis
Immunophenotype: CD2⁺, CD3⁺, CD7⁺, CD4⁻, CD8⁻, TCR γδ⁺
Cytogenetics: Isochromosome 7q, trisomy 8
Flow cytometry may detect atypical T cells

Clinical Course and Prognosis

Rapid progression, often fulminant
Median survival <1 year
High relapse rate even after initial response
Early aggressive therapy may improve outcomes

Treatment Strategies

CHOP often ineffective (cyclophosphamide, doxorubicin, vincristine, prednisone)
Intensive regimens: HyperCVAD, ICE, FLAG-IDA
Allogeneic stem cell transplant offers best chance for remission
Experimental therapies: JAK/STAT inhibitors, chromatin-modifying agents

Summary Table

Aspect	Details
Risk meds	Thiopurines + anti-TNF agents
Affected group	Young males with IBD or transplant
Symptoms	Fever, splenomegaly, cytopenias
Diagnosis	Biopsy + immunophenotyping
Prognosis	Poor, median survival <1 year
Treatment	Intensive chemo + stem cell transplant